Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease

Multicentric study on the beta-blocker use and relation with exacerbations in COPD

Puente-Maestu, Luis
Calle, Myriam
Ortega-González, Ángel
Fuster, Antonia
González, Cruz
Márquez-Martín, Eduardo
Marcos-Rodriguez, Pedro Jorge
Calero, Carmen
Rodríguez-Hermosa, Juan Luis
Malo de Molina, Rosa
Aburto, Myriam
Sobradillo, Patricia
Alcázar, Bernardino
Tirado-Conde, Gema

May 2014

SummaryChronic obstructive pulmonary disease (COPD) is frequently associated with chronic heart fail...

082 Chronic obstructive pulmonary disease: the new deal for b-blocker prescription in chronic heart failure

Galinier, Michel
Demil, Nacima
Assyag, Patrick
De Groote, Pascal
Isnard, Richard
Jondeau, Guillaume
Ducardonnet, Alain
Thébaut, Jean-François
Komajda, Michel

January 2010

BackgroundThe recent European Guidelines for the treatment of CHF 2008 underlined that the majority ...

Effect of β blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records.

Quint, JK
Herrett, E
Bhaskaran, K
Timmis, A
Hemingway, H
Wedzicha, JA
Smeeth, L

January 2013

OBJECTIVES: To investigate whether the use and timing of prescription of β blockers in patients with...

Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease

Lipworth, Brian
Skinner, Derek
Devereux, Graham
Thomas, Victoria
Zhi Jie, Joanna Ling
Martin, Jessica
Carter, Victoria
Price, David B

December 2016

Acknowledgments The data in this article have been partly presented in preliminary abstract form as ...

β-Blocker Therapy and Risk of Chronic Obstructive Pulmonary Disease – A Danish Nationwide Study of 1·3 Million Individuals

Anne Orholm Nielsen
Lars Pedersen
Birgitte Fischer Sode
Morten Dahl

January 2019

Background: The possible association between β-adrenoceptor antagonists (β-blockers) and risk of COP...

Certainties fading away: β-blockers do not worsen chronic obstructive pulmonary disease

Verdecchia P.
Cavallini C.
Coiro S.
Riccini C.
Angeli F.

January 2021

For many years, β-blockers have been considered contraindicated in patients with heart failure (HF) ...

Effect of β-blockers on the risk of COPD exacerbations according to indication of use: the Rotterdam Study

Leila Karimi
Lies Lahousse
Phebe De Nocker
Bruno H. Stricker
Guy G. Brusselle
Katia M.C. Verhamme

June 2021

Observational studies report a reduction of COPD exacerbations in patients treated with β-blockers. ...

Beta-Blocker Use in Older Hospitalized Patients Affected by Heart Failure and Chronic Obstructive Pulmonary Disease: An Italian Survey From the REPOSI Register

Arcoraci V.
Squadrito F.
Rottura M.
Barbieri M. A.
Pallio G.
Irrera N.
Nobili A.
Natoli G.
Argano C.
Squadrito G.
Corrao S.

January 2022

Beta (β)-blockers (BB) are useful in reducing morbidity and mortality in patients with heart failure...

Effect of β-blockade on lung function, exercise performance and dynamic hyperinflation in people with arterial vascular disease with and without COPD.

Key, Angela
Parry, Matthew
West, Malcolm A
Asher, Rebecca
Jack, Sandy
Duffy, Nick
Torella, Francesco
Walker, Paul P

April 2017

INTRODUCTION: β Blockers are important treatment for ischaemic heart disease and heart failure; howe...

Protective Effects of Bisoprolol against Acute Exacerbation in Moderate-to-Severe Chronic Obstructive Pulmonary Disease

Taniguchi, Akihiko
Miyahara, Nobuaki
Oda, Naohiro
Morichika, Daisuke
Ichihara, Eiki
Oze, Isao
Tanimoto, Yasushi
Ichikawa, Hirohisa
Fujii, Utako
Tanimoto, Mitsune
Kanehiro, Arihiko
Kiura, Katsuyuki

October 2017

Although recent retrospective studies suggested that the use of β-blockers appears to help improve t...

β-Blockers are associated with a reduction in COPD exacerbations

Bhatt, Surya P
Wells, James M
Kinney, Gregory L
Washko, George R
Budoff, Matthew
Kim, Young-il
Bailey, William C
Nath, Hrudaya
Hokanson, John E
Silverman, Edwin K
Crapo, James
Dransfield, Mark T

January 2016

BackgroundWhile some retrospective studies have suggested that β-blocker use in patients with COPD i...

Association between â-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension

Stefan, Mihaela, MD
Rothberg, Michael, MD
Pekow, Penny
Lindenauer, Peter, MD

November 2012

BACKGROUND: Î²-Blocker therapy has been shown to improve survival among patients with ischaemic hear...

Beta-blockers in COPD:time for reappraisal

Lipworth, Brian
Wedzicha, Jadwiga
Devereux, Graham
Vestbo, Jørgen
Dransfield, Mark T.

September 2016

The combined effects on the heart of smoking and hypoxaemia may contribute to an increased cardiovas...

Beta-blocker use in patients with chronic obstructive pulmonary disease: A systematic review: A systematic review of βB in COPD

Ruzieh, Mohammed
Baugh, Aaron D
Al Jebbawi, Lama N
Edwards, Emily S
Jia, Kelly Qi
Dransfield, Mark T
Foy, Andrew J

January 2023

Beta-blockers (βB) are a frequently used class of medications. Although βB have many indications, th...

Beta-blocker under-use in COPD patients

Lim, Kuan Pin
Loughrey, Sarah
Musk, Michael
Lavender, Melanie
Wrobel, Jeremy P

January 2017

Background: Cardiovascular (CVS) comorbidities are common in COPD and contribute significantly to mo...

Multicentric study on the beta-blocker use and relation with exacerbations in COPD

Puente-Maestu, Luis
Calle, Myriam
Ortega-González, Ángel
Fuster, Antonia
González, Cruz
Márquez-Martín, Eduardo
Marcos-Rodriguez, Pedro Jorge
Calero, Carmen
Rodríguez-Hermosa, Juan Luis
Malo de Molina, Rosa
Aburto, Myriam
Sobradillo, Patricia
Alcázar, Bernardino
Tirado-Conde, Gema

May 2014

SummaryChronic obstructive pulmonary disease (COPD) is frequently associated with chronic heart fail...

082 Chronic obstructive pulmonary disease: the new deal for b-blocker prescription in chronic heart failure

Galinier, Michel
Demil, Nacima
Assyag, Patrick
De Groote, Pascal
Isnard, Richard
Jondeau, Guillaume
Ducardonnet, Alain
Thébaut, Jean-François
Komajda, Michel

January 2010

BackgroundThe recent European Guidelines for the treatment of CHF 2008 underlined that the majority ...

Effect of β blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records.

Quint, JK
Herrett, E
Bhaskaran, K
Timmis, A
Hemingway, H
Wedzicha, JA
Smeeth, L

January 2013

OBJECTIVES: To investigate whether the use and timing of prescription of β blockers in patients with...

Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease

Lipworth, Brian
Skinner, Derek
Devereux, Graham
Thomas, Victoria
Zhi Jie, Joanna Ling
Martin, Jessica
Carter, Victoria
Price, David B

December 2016

Acknowledgments The data in this article have been partly presented in preliminary abstract form as ...

β-Blocker Therapy and Risk of Chronic Obstructive Pulmonary Disease – A Danish Nationwide Study of 1·3 Million Individuals

Anne Orholm Nielsen
Lars Pedersen
Birgitte Fischer Sode
Morten Dahl

January 2019

Background: The possible association between β-adrenoceptor antagonists (β-blockers) and risk of COP...

Certainties fading away: β-blockers do not worsen chronic obstructive pulmonary disease

Verdecchia P.
Cavallini C.
Coiro S.
Riccini C.
Angeli F.

January 2021

For many years, β-blockers have been considered contraindicated in patients with heart failure (HF) ...

Effect of β-blockers on the risk of COPD exacerbations according to indication of use: the Rotterdam Study

Leila Karimi
Lies Lahousse
Phebe De Nocker
Bruno H. Stricker
Guy G. Brusselle
Katia M.C. Verhamme

June 2021

Observational studies report a reduction of COPD exacerbations in patients treated with β-blockers. ...

Beta-Blocker Use in Older Hospitalized Patients Affected by Heart Failure and Chronic Obstructive Pulmonary Disease: An Italian Survey From the REPOSI Register

Arcoraci V.
Squadrito F.
Rottura M.
Barbieri M. A.
Pallio G.
Irrera N.
Nobili A.
Natoli G.
Argano C.
Squadrito G.
Corrao S.

January 2022

Beta (β)-blockers (BB) are useful in reducing morbidity and mortality in patients with heart failure...

Effect of β-blockade on lung function, exercise performance and dynamic hyperinflation in people with arterial vascular disease with and without COPD.

Key, Angela
Parry, Matthew
West, Malcolm A
Asher, Rebecca
Jack, Sandy
Duffy, Nick
Torella, Francesco
Walker, Paul P

April 2017

INTRODUCTION: β Blockers are important treatment for ischaemic heart disease and heart failure; howe...

Protective Effects of Bisoprolol against Acute Exacerbation in Moderate-to-Severe Chronic Obstructive Pulmonary Disease

Taniguchi, Akihiko
Miyahara, Nobuaki
Oda, Naohiro
Morichika, Daisuke
Ichihara, Eiki
Oze, Isao
Tanimoto, Yasushi
Ichikawa, Hirohisa
Fujii, Utako
Tanimoto, Mitsune
Kanehiro, Arihiko
Kiura, Katsuyuki

October 2017

Although recent retrospective studies suggested that the use of β-blockers appears to help improve t...

β-Blockers are associated with a reduction in COPD exacerbations

Bhatt, Surya P
Wells, James M
Kinney, Gregory L
Washko, George R
Budoff, Matthew
Kim, Young-il
Bailey, William C
Nath, Hrudaya
Hokanson, John E
Silverman, Edwin K
Crapo, James
Dransfield, Mark T

January 2016

BackgroundWhile some retrospective studies have suggested that β-blocker use in patients with COPD i...

Association between â-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension

Stefan, Mihaela, MD
Rothberg, Michael, MD
Pekow, Penny
Lindenauer, Peter, MD

November 2012

BACKGROUND: Î²-Blocker therapy has been shown to improve survival among patients with ischaemic hear...

Beta-blockers in COPD:time for reappraisal

Lipworth, Brian
Wedzicha, Jadwiga
Devereux, Graham
Vestbo, Jørgen
Dransfield, Mark T.

September 2016

The combined effects on the heart of smoking and hypoxaemia may contribute to an increased cardiovas...

Beta-blocker use in patients with chronic obstructive pulmonary disease: A systematic review: A systematic review of βB in COPD

Ruzieh, Mohammed
Baugh, Aaron D
Al Jebbawi, Lama N
Edwards, Emily S
Jia, Kelly Qi
Dransfield, Mark T
Foy, Andrew J

January 2023

Beta-blockers (βB) are a frequently used class of medications. Although βB have many indications, th...

Beta-blocker under-use in COPD patients

Lim, Kuan Pin
Loughrey, Sarah
Musk, Michael
Lavender, Melanie
Wrobel, Jeremy P

January 2017

Background: Cardiovascular (CVS) comorbidities are common in COPD and contribute significantly to mo...

Multicentric study on the beta-blocker use and relation with exacerbations in COPD

Puente-Maestu, Luis
Calle, Myriam
Ortega-González, Ángel
Fuster, Antonia
González, Cruz
Márquez-Martín, Eduardo
Marcos-Rodriguez, Pedro Jorge
Calero, Carmen
Rodríguez-Hermosa, Juan Luis
Malo de Molina, Rosa
Aburto, Myriam
Sobradillo, Patricia
Alcázar, Bernardino
Tirado-Conde, Gema

May 2014

SummaryChronic obstructive pulmonary disease (COPD) is frequently associated with chronic heart fail...

082 Chronic obstructive pulmonary disease: the new deal for b-blocker prescription in chronic heart failure

Galinier, Michel
Demil, Nacima
Assyag, Patrick
De Groote, Pascal
Isnard, Richard
Jondeau, Guillaume
Ducardonnet, Alain
Thébaut, Jean-François
Komajda, Michel

January 2010

BackgroundThe recent European Guidelines for the treatment of CHF 2008 underlined that the majority ...

Effect of β blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records.

Quint, JK
Herrett, E
Bhaskaran, K
Timmis, A
Hemingway, H
Wedzicha, JA
Smeeth, L

January 2013

OBJECTIVES: To investigate whether the use and timing of prescription of β blockers in patients with...

Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease

Abstract

Extracted data

Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease

Abstract

Extracted data

Related items

Related items